Emmanuel Bijaoui, MEng, is Founder & CEO of Treat Therapeutics, the first decentralized research platform for companion-animal health. After earning his masters in biomedical-engineering at the University College London, he subsequently worked as a researcher his research focusing on the development of predictive models for dementia. Following a stint in academia, he proceeded to join a microbiome startup where he lead data analysis , translating microbial signatures into nutrition advice.
In 2022 he launched Treat to deliver fast, home-based trials to veterinary R&D. Treat has run 20 + industry studies on four continents and maintains a 7,000-pet wait-list of home-based dogs & cats. Its protocols blend validated behaviour surveys, wearables, and cloud analytics to test probiotics, diets, and therapeutics in real-world settings at a fraction of legacy cost.
Emmanuel’s interests span AI phenotyping, multi-omics, translational and One Health. He has been invited as a guest speaker at London Vet Show, Interzoo, and AHNTI USA, and conducted research for a wide variety of partners and indications including gastrointestinal concerns, kidney disease, UTI and atopic dermatitis in dogs & cats.
Emmanuel aims to harness data-rich, pet-centric trials to speed safe therapies that extend healthy lifespan for animals - and eventually people.
Emmanuel Bijaoui, MEng, is Founder & CEO of Treat Therapeutics, the first decentralized research platform for companion-animal health. After earning his masters in biomedical-engineering at the University College London, he subsequently worked as a researcher his research focusing on the development of predictive models for dementia. Following a stint in academia, he proceeded to join a microbiome startup where he lead data analysis , translating microbial signatures into nutrition advice.
In 2022 he launched Treat to deliver fast, home-based trials to veterinary R&D. Treat has run 20 + industry studies on four continents and maintains a 7,000-pet wait-list of home-based dogs & cats. Its protocols blend validated behaviour surveys, wearables, and cloud analytics to test probiotics, diets, and therapeutics in real-world settings at a fraction of legacy cost.
Emmanuel’s interests span AI phenotyping, multi-omics, translational and One Health. He has been invited as a guest speaker at London Vet Show, Interzoo, and AHNTI USA, and conducted research for a wide variety of partners and indications including gastrointestinal concerns, kidney disease, UTI and atopic dermatitis in dogs & cats.
Emmanuel aims to harness data-rich, pet-centric trials to speed safe therapies that extend healthy lifespan for animals - and eventually people.